Ventures

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

SERDA presents a solution for wound debridement, particularly useful for burn wounds and chronic wounds like diabetic foot ulcers. Traditional debridement methods can be expensive, painful, or less effective. SERDA offers an enzymatic debrider in the form of a hydrogel that selectively breaks down necrotic tissue, leaving healthy tissue intact, promoting faster healing with minimal discomfort for the patient. SERDA aims to improve the efficiency and ease of wound care, providing a more effective alternative to existing options.

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

Sigilla Medical is developing an innovative, implant-free radiofrequency device designed to close PFOs (patent foramen ovale) in stroke-risk patients. PFOs are associated with cryptogenic stroke and migraine, and current treatment involves placing a large metal device that spans the septum of the heart in an otherwise young and healthy patient. Sigilla’s device offers a safer, more efficient alternative by using controlled radiofrequency to seal the PFO without the need for implants. This less-invasive approach reduces procedural risk and adverse cardiac events while leaving options open for future minimally invasive procedures.

Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid treatment for peripheral neuropathy, addressing a market with over 500 million patients globally. Their GalR2 agonist delivers dual action that no current therapy offers: potent pain relief and nerve regeneration. Critically, NLV-01 does not cross the blood-brain barrier, eliminating the CNS side effects and addiction risk that limit opioids and gabapentinoids.